LAT2 regulates glutamine-dependent mTOR activation to promote glycolysis and chemoresistance in pancreatic cancer.

LAT2 regulates glutamine-dependent mTOR activation to promote glycolysis and chemoresistance in pancreatic cancer.
复制标题

LAT2 调节谷氨酰胺依赖性 mTOR 激活,促进胰腺癌中的糖酵解和化疗耐药。

DOI:
10.1186/s13046-018-0947-4
复制
发表时间:
2018-11-12
期刊:
Journal of experimental & clinical cancer research : CR
影响因子:
--
通讯作者:
Zhao Y
Zhao Y
中科院分区:
其他
文献类型:
--
作者:
Feng M;Xiong G;Cao Z;Yang G;Zheng S;Qiu J;You L;Zheng L;Zhang T;Zhao Y

文献摘要

参考文献

被引文献

相似文献

Reprogrammed energy metabolism has become an emerging hallmark of cancer in recent years. Transporters have been reported to be amino acid sensors involved in controlling mTOR recruitment and activation, which is crucial for the growth of both normal and tumor cells. L-type amino acid transporter 2 (LAT2), encoded by the SLC7A8 gene, is a Na+-independent neutral amino acid transporter and is responsible for transporting neutral amino acids, including glutamine, which can activate mTOR. Previous studies have shown that LAT2 was overexpressed in gemcitabine-resistant pancreatic cancer cells. However, the role of LAT2 in chemoresistance in pancreatic cancer remains uncertain and elusive. The effects of LAT2 on biological behaviors were analyzed. LAT2 and LDHB levels in tissues were detected, and the clinical value was evaluated. We demonstrated that LAT2 emerged as an oncogenic protein and could decrease the gemcitabine sensitivity of pancreatic cancer cells in vitro and in vivo. The results of a survival analysis indicated that high expression levels of both LAT2 and LDHB predicted a poor prognosis in patients with pancreatic cancer. Furthermore, we found that LAT2 could promote proliferation, inhibit apoptosis, activate glycolysis and alter glutamine metabolism to activate mTOR in vitro and in vivo. Next, we found that gemcitabine combined with an mTOR inhibitor (RAD001) could reverse the decrease in chemosensitivity caused by LAT2 overexpression in pancreatic cancer cells. Mechanistically, we demonstrated that LAT2 could regulate two glutamine-dependent positive feedback loops (the LAT2/p-mTORSer2448 loop and the glutamine/p-mTORSer2448/glutamine synthetase loop) to promote glycolysis and decrease gemcitabine (GEM) sensitivity in pancreatic cancer. Taken together, our data reveal that LAT2 functions as an oncogenic protein and could regulate glutamine-dependent mTOR activation to promote glycolysis and decrease GEM sensitivity in pancreatic cancer. The LAT2-mTOR-LDHB pathway might be a promising therapeutic target in pancreatic cancer. The online version of this article (10.1186/s13046-018-0947-4) contains supplementary material, which is available to authorized users.
癌细胞中沃尔堡效应与谷氨酰胺分解代谢的偶联成瘾。
DOI: 10.1016/j.celrep.2016.09.045
发表时间: 2016-10-11
期刊: Cell reports
影响因子: 8.8
作者:
Smith B;Schafer XL;Ambeskovic A;Spencer CM;Land H;Munger J
通讯作者: Munger J
DOI: 10.4137/bmi.s30559
发表时间: 2015
期刊: Biomarker insights
影响因子: 3.8
作者:
Thakkar A;Raj H;Ravishankar;Muthuvelan B;Balakrishnan A;Padigaru M
通讯作者: Padigaru M
DOI: 10.1038/msb.2011.56
发表时间: 2011-08-01
影响因子: 9.9
作者:
Gaglio, Daniela;Metallo, Christian M.;Chiaradonna, Ferdinando
通讯作者: Chiaradonna, Ferdinando
DOI: 10.1016/s0140-6736(17)33326-3
发表时间: 2018-03-17
期刊: Lancet (London, England)
影响因子: --
作者:
Allemani C;Matsuda T;Di Carlo V;Harewood R;Matz M;Nikšić M;Bonaventure A;Valkov M;Johnson CJ;Estève J;Ogunbiyi OJ;Azevedo E Silva G;Chen WQ;Eser S;Engholm G;Stiller CA;Monnereau A;Woods RR;Visser O;Lim GH;Aitken J;Weir HK;Coleman MP;CONCORD Working Group
通讯作者: CONCORD Working Group
DOI: 10.1126/science.1259472
发表时间: 2015-01-09
期刊: Science (New York, N.Y.)
影响因子: --
作者:
Jewell JL;Kim YC;Russell RC;Yu FX;Park HW;Plouffe SW;Tagliabracci VS;Guan KL
通讯作者: Guan KL